Get the Stockscreener App
87.41
0.93%
-0.82
Pre-market:
86.51
-0.90
-1.03%
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision Medicines (NASDAQ:PRAX) Trading 5.8% HigherStill a Buy? - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 52-Week HighStill a Buy? - MarketBeat
China Universal Asset Management Co. Ltd. Invests $304,000 in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Morgan Stanley's Strategic Acquisition of Praxis Precision Medic - GuruFocus.com
Should You Invest in Nasdaq Inc (NDAQ) Now? - The News Heater
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Praxis Precision Medicines to Present at Two February Investor Conferences - The Manila Times
CNS Drug Developer Praxis Lines Up Exclusive Investor Access at Guggenheim & Oppenheimer Events - StockTitan
Learn to Evaluate (PRAX) using the Charts - Stock Traders Daily
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Praxis Precision Medicines (PRAX) Stock Price, News & Analysis - MarketBeat
Jefferies maintains Praxis stock with $305 target, bullish on catalysts - MSN
Noteworthy Wednesday Option Activity: PRAX, ORCL, SOC - Nasdaq
Jefferies maintains Praxis stock with $305 target, bullish on catalysts By Investing.com - Investing.com South Africa
Truist Financial Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 8.5% Following Analyst Upgrade - Defense World
Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts - Benzinga
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 8.5% Following Analyst Upgrade - MarketBeat
Truist raises Praxis stock target to $175 on study optimism - MSN
Truist raises Praxis stock target to $175 on study optimism By Investing.com - Investing.com Australia
Praxis Precision Medicines (NASDAQ:PRAX) Given New $175.00 Price Target at Truist Financial - MarketBeat
Ellsworth Advisors LLC Takes $627,000 Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest Update - MarketBeat
Trend Tracker for (PRAX) - Stock Traders Daily
Assenagon Asset Management S.A. Has $43.03 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines Unveils Ambitious 2025 Strategy: 4 Pivotal Trial Readouts, $470M Cash Runway - StockTitan
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities - The Bakersfield Californian
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 8.9%Here's Why - MarketBeat
(PRAX) Trading Report - Stock Traders Daily
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference - The Manila Times
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Long Term Trading Analysis for (PRAX) - Stock Traders Daily
Geode Capital Management LLC Has $22.95 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by Barclays PLC - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Acquired by Barclays PLC - MarketBeat
Praxis Precision Medicines: Multiple Potential Drivers (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines Inc (NASDAQ: PRAX) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Franklin Resources Inc. Grows Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
State Street Corp Has $45.44 Million Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $913,000 Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Technical Data - Stock Traders Daily
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine - The Bakersfield Californian
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome - GlobeNewswire
Praxis Precision Medicines Secures Key FDA Designation for Promising Epilepsy Drug Relutrigine - StockTitan
Praxis Precision Medicines (NASDAQ:PRAX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Wellington Management Group LLP Buys 168,394 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):